Study of Oral Alpha-Lipoic Acid to Protect Kidneys During Cisplatin Chemotherapy for Solid Tumors

What this Trial Is About

Researchers are evaluating the potential protective effect of Alpha-Lipoic Acid ALA against kidney damage caused by cisplatin chemotherapy in patients with solid tumors. This proof-of-concept, randomized, controlled, open-label clinical trial aims to assess changes in kidney function when ALA is added to standard preventive care during cisplatin treatment. The study is sponsored by Minia University and focuses on monitoring kidney health in oncology patients receiving cisplatin-based regimens. Participants are randomly assigned to one of two groups. Both groups receive standard preventive measures such as hydration, antiemetics, and mineral supplementation. The experimental group also takes oral Alpha-Lipoic Acid twice daily, starting two days before the first cisplatin dose and continuing throughout each chemotherapy cycle, for up to four cycles. The control group receives only standard preventive care alongside their chemotherapy. During the study, researchers monitor kidney function weekly for up to six weeks, assessing serum creatinine and creatinine clearance levels. They also evaluate patients quality of life and track occurrences of acute kidney injury, as well as any cisplatin dose changes due to kidney issues. Participants are followed closely throughout the treatment period to gather data on kidney health and safety outcomes related to the addition of ALA.

Alpha-Lipoic Acid in Mitigating Cisplatin-Induced Nephrotoxicity